

# eve

HEALTH GROUP

---

TRANSFORMATIONAL ACQUISITION

# NEXTRACT

REFORMULATING A PROVEN DRUG TARGETING

THE \$5.3B ERECTILE DYSFUNCTION MARKET

ENHANCED SOLUBILITY DESIGNED FOR FASTER ACTION AND HIGHER EFFICACY

# Important Notice and Disclaimer

This presentation has been prepared by and issued by Eve Health Group Limited, to assist it in informing interested parties about the Company and its progress. It should not be considered as an offer or invitation to subscribe for or purchase any securities in the Company or as an inducement to make an offer or invitation with respect to those securities. No agreement to subscribe for securities in the Company will be entered into on the basis of this presentation.

You should not act or refrain from acting in reliance on this presentation material. This overview of Eve Health Group Limited does not purport to be all inclusive or to contain all information that its recipients may require in order to make an informed assessment of the Company's prospects. You should conduct your own investigation and perform your own analysis in order to satisfy yourself as to the accuracy and completeness of the information, statements and opinions contained in this presentation and making any investment decision.

Eve Health Group Limited has not verified the accuracy or completeness of the information, statements and opinions contained in this presentation. Accordingly, to the maximum extent permitted by law, the Company makes no representation and give no assurance, guarantee or warranty, express or implied, as to, and takes no responsibility and assume no liability for, the authenticity, validity, accuracy, suitability or completeness of, or any errors in or omission, from any information, statement or opinion contained in this presentation.

This presentation contains forward-looking statements regarding the Company's intentions and future business, including the future business of its subsidiaries. These statements reflect current information, expectations, intentions and strategies regarding the future, and are subject to certain risks and uncertainties. Should one or more of these risks or uncertainties materialise, or should any of the underlying assumptions prove incorrect, actual results may vary from the expectations, intentions and strategies described in this presentation. Investors are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date they are made. Other than where required by law, the Company is under no obligation to revise any forward-looking statement to reflect events or circumstances after the date of this presentation or to reflect the occurrence of unanticipated events.

All product-related statements in this presentation reflect formulation design intent, or anecdotal user-reported outcomes from early-stage evaluations. These statements are not intended to imply proven clinical efficacy or therapeutic equivalence to existing products. Clinical trials and regulatory assessments are ongoing or pending, and outcomes are subject to change. Investors should not rely on forward-looking statements as guarantees of future performance.

*Authorised for release* - This announcement was authorised for release by Bill Fry, Managing Director.

# Executive Summary

**Eve Health Overview:** Eve Health Group specialises in innovative health solutions, enhancing patient care across various medical sectors. It currently owns Meluka Australia which targets gut health and generates approximately \$2m in revenue in DTC sales.

**Nextract Acquisition:** Nextract improves treatment of sexual and reproductive health for men and women starting with erectile dysfunction (ED) and dysmenorrhea (period pain).



**Repurposed Pharmaceutical Drugs** by improving the solubility of already proven formulations Nextract's products improve the speed to effectiveness to be best in market.



**Products for ED and dysmenorrhea have been developed** and are currently undergoing stability studies ahead of submission to the TGA for approval. Product efficacy and manufacturing processes are already in place.



Disrupting the **US\$5.3<sup>1</sup> billion ED and US\$10.9<sup>2</sup> billion Dysmenorrhea global markets.**



**Rapid Path to Commercialisation in Australia** with regulatory approval expected within 3-6 months following submission and first sales commencing immediately following manufacture via SAS-B channel. Sales expected to commence by Q1 2026.



**Market Position Advantage:** Nextract occupies a pivotal market role with broad experience in navigating regulatory approvals. Nextract offers unique products that complement Eve Health's existing offerings and can elevate these products to delivering a broad range of commercialised medical solutions within a short period of time.

# Directors and Management



## **DAMIAN WOOD** **PROPOSED MANAGING DIRECTOR**

Damian is a registered industrial pharmacist with experience as a frontline hospital clinician, pharmaceutical manufacturer, and business development lead.



## **Dr STUART GUNZBURG** **CSO**

Stuart has a PHD specialising in drug formulation and solubility science. His work focuses on nano-emulsion drug delivery technology to optimise absorption.



## **ROD HANNINGTON** **Non-Executive Chairman**

Rod has over 25 years of experience working across FMCG and healthcare start-ups. He has held a variety of board roles at ASX-listed companies, with a particular focus in the consumer health space.



## **BILL FRY** **NON-EXECUTIVE DIRECTOR**

Bill has over 20 years corporate experience specialising in investment management, finance, project evaluation, development and management.



## **BEN ROHR** **COO**

Ben is an experienced business leader with a track record of growing brands across international markets. He has deep expertise in the Food & Beverage, Health, and Technology sectors, with a particular focus on nutraceuticals and wellness. He has led businesses in both Australia and the US.



## **STEVEN JACKSON** **COMPANY SECRETARY & CFO**

Steven has worked across a range of industries dealing with acquisitions, investment analysis and financing.

# The Market Demand for ED Solutions



**40%**<sup>1</sup>

of men at age 40

**70%**

of men at age 70



Phosphodiesterase 5 inhibitors (PDE5Is) are the first-line ED therapy. PDE5Is: Viagra, Cialis, Levitra

**60% -70%**<sup>2</sup>

Patients report a positive outcome

Up to **60 min**

Response time for PDE5Is

**50%**

Patients stop purchasing PDE5Is



**USD 5.3b**<sup>3</sup>

Market Size 2025

**7.6%**

CAGR from 2025 - 2032



**322m**<sup>4</sup>

Men globally are projected to be affected by erectile dysfunction in 2025

Men that are impacted by erectile dysfunction



**30m**



**150m**



**8m**

<sup>1</sup> Feldman et al. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994; 151:54-61, January 1994

<sup>2</sup> Carvalho et al., "Dropout in the Treatment of Erectile Dysfunction with PDE5: A Study on Predictors and a Qualitative Analysis of Reasons for Discontinuation," Journal of Sexual Medicine, May 2012.

<sup>3</sup> Coherent Market Insights - <https://www.coherentmarketinsights.com/market-insight/erectile-dysfunction-market-200>

<sup>4</sup> Frost and Sullivan Report, The Erectile Dysfunction Medicines Market, September 2023

# The Nextract ED Solution

**Proprietary Solubility Technology:** Nextract's proprietary nanoemulsion platform is designed to enhance solubility and bioavailability.<sup>2</sup>

**Nextract Research:** Solubilised PDE5Is.

**Solubilised Advantage:** Nextract's formulation aims to improve absorption of Tadalafil, with an intended effective dose of 10mg.<sup>2</sup>

**Nextract Formulation** approach is intended to support improved mucosal absorption and onset.<sup>2</sup>

**Solutions:** Oral breath freshening strip, chewing gum and gummies.

## PRODUCT

## TIME TO EFFECTIVENESS

### Nextract

5 – 15 minutes<sup>1</sup>

**Viagra**  
(Sildenafil)

30 – 60 minutes

**Cialis**  
(Tadalafil)

30 – 60 minutes

**Levitra**  
(Vardenafil)

25 – 60 minutes

## KEY TARGETS

**100%<sup>1</sup>**

Effectiveness from  
60% - 70% with Tadalafil<sup>1</sup>

**< 10 min**

Time to effect from  
+/- 60 min with Tadalafil



Remove the  
**Stigma**


Associated with using pills and nasal sprays.

<sup>1</sup> Based on formulation design, known compound properties, and a 10-person observational study, where all participants responded within 15 minutes to a 10mg Tadalafil oral film. Comparator data from published averages. Clinical validation pending.

<sup>2</sup> Preliminary claims supported by Provisional Patent Application No. 2024902673 (IP Australia), describing a nanoemulsion-based transmucosal delivery platform intended to improve solubility and absorption. Clinical validation pending.

# Product Pipeline and Development Timeline

## ED Solution





# Path to Market



**Regulatory Fast-Tracking in Australia:** TGA access pathways for potentially faster commercialisation via (i) SAS-B<sup>1</sup>, (ii) Authorised Prescriber, (iii) ARTG Export Only. These frameworks enable expedited access for innovative therapies for unmet clinical need. Vital for timely market entry.



**US Regulatory Pathways:** The FDA 505(b)(2) application offers a streamlined approval for Nextra products, potentially enabling earlier commercialisation in the US market.



**Importance of Regulatory Approval:** Successful navigation of regulatory processes assures investors of reduced time-to-market and enhanced revenue potential.



# The Nextract Dysmenorrhea Solution

**Addressable Market:** Global market size of US\$10.9b<sup>1</sup> in 2024

**Proprietary Solubility Technology:** Nextract's formulation is designed to enhance solubility and support rapid absorption through a proprietary nanoemulsion-based delivery platform.<sup>3</sup>

**Nextract Research & Formulation:** Dysmenorrhea pain relief with reduced potential for adverse effects and improved bioavailability for prompt pain relief.

**Solution:** gelcap and gummies.

**Pathway to Market:** Similar to ED product however sales can commence as soon as it's submitted to the TGA.

PRODUCT	TIME TO EFFECTIVENESS
<b>Nextract</b>	5 – 15 minutes <sup>2</sup>
<b>NSAID</b> (E.g. Ibuprofen, Naproxen)	30 – 60 minutes
<b>Hormonal Contraceptives</b> (E.g. Birth Control Pills, IUDs)	Several days to weeks


## KEY TARGETS

### Non-Hormonal

Naturally-derived products

### Fast Acting

Specifically formulated for improved uptake



### Reduced Adverse Effects

No hormones, no NSAIDs

<sup>1</sup> IMARC Group, Dysmenorrhea Market Outlook 2025-2035 - [www.imarcgroup.com/dysmenorrhea-market-outlook](https://www.imarcgroup.com/dysmenorrhea-market-outlook)

<sup>2</sup> Target onset and bioavailability are based on known properties of active compounds and preliminary formulation design. Further clinical validation is required. Data shown for comparator products is based on published average ranges.

<sup>3</sup> Note: Bioavailability and performance outcomes are subject to confirmation via clinical evaluation. Provisional Patent Application No. 2024902673 outlines nanoemulsion delivery for transmucosal absorption. Preliminary user outcomes suggest favourable onset profile; clinical validation is pending.

# Transaction Structure and Indicative Timetable

	Pre-Consolidation	Post-Consolidation <sup>1</sup>
Existing Shares	5,274,482,664	131,862,067
Vendor Shares	3,333,333,333	83,333,333
Placement Shares	1,111,111,120	27,777,778
Share Purchase Plan Shares <sup>2</sup>	555,555,547	13,888,889
Facilitation Shares <sup>3</sup>	140,000,000	3,500,000
<b>Total Shares</b>	<b>10,414,482,664</b>	<b>260,362,067</b>

<sup>1</sup> Subject to rounding up of fractional entitlements

<sup>2</sup> Maximum number of shares to be issued under the Share Purchase Plan

<sup>3</sup> To be issued pro-rata subject to Lead Manager raising up to \$1.5 million within 12 months, Facilitation Shares will be issued under the Company's placement capacity or subject to shareholder approval

Event	Date
Record Date for Share Purchase Plan	11 April 2025
Announcement of Nextextract Transaction, Placement, Share Purchase Plan and Share Consolidation	14 April 2025
Meeting of Shareholders / Effective Date of Consolidation	21 May 2025
Last Date for Trading in Pre-Consolidation Securities	22 May 2025
Trading in Post-Consolidation Securities commences on a deferred settlement basis	23 May 2025
Record Date for Consolidation	26 May 2025
Estimated Completion of Nextextract Transaction, including Issue of Vendor Shares, Placement Shares and Facilitation Shares	2 June 2025
First day for normal trading on post-Consolidation basis	3 June 2025
Dispatch of Share Purchase Plan Booklet and Offer Open	3 June 2025
Closing Date for Share Purchase Plan	13 June 2025
Announcement of Results of Share Purchase Plan and Issue of Share Purchase Plan Shares	18 June 2025

# Investment Rationale

The purchase of Nextract will provide EVE with the capacity to quickly become a vertically integrated pharmaceutical and food manufacturer with a ready portfolio of health-related products.

## EXPEDITED PATH TO MARKET



Leveraging simplified regulatory approvals and development timelines to accelerate market entry.

## MASSIVE ADDRESSABLE MARKET



A large, growing market actively seeking alternative solutions in pharmaceutical delivery.

## SEAMLESS INTEGRATION WITH MELUKA



Nextract complements Meluka Australia's existing operations, contributing to a growing revenue stream of \$2m.

## SIGNIFICANT SHORT-TERM MILESTONES



Clear, achievable goals within the next 12 months to demonstrate progress and value.

## SCALABLE R&D AND BUSINESS MODEL



Efficient research and development processes, enabling fast commercialisation and growth.

# Sources and Uses of Funds

## NEXTRACT - USE OF FUNDS

### ED - A\$0.3m

- Stability Testing
- Regulatory Approval
- Marketing/Production

### Dysmenorrhea - A\$0.2m

- Stability Testing
- Regulatory Approval
- Marketing/Production



## Sources of Funds

Sources of Funds	A\$m
Placement	1.0
Share Purchase Plan <sup>1</sup>	0.5
Existing cash (as at 31 March 2025)	0.3
<b>Total Sources</b>	<b>1.8</b>

## Uses of Funds

Uses of Funds	A\$m
Nextract	0.5
Meluka Australia	0.2
Working capital and Offer Costs	1.1
<b>Total Use of Funds</b>	<b>1.8</b>

<sup>1</sup> Assumes full subscription for SPP

# About Meluka Australia



**Meluka Australia Overview:** Meluka Australia is dedicated to delivering premium, taste-focused gut health solutions, leveraging the unique benefits of its proprietary *Lactobacillus rhamnosus* Beebiotic MAP01® strain.



Meluka Australia delivers approximately **\$2m of annual revenue** from its Australian DTC business.



**Commitment to Gut Health:** Meluka Australia's range of tonics and powders is designed to support both general gut health and specific digestive concerns, offering targeted solutions backed by innovation and research.



Meluka's established e-commerce, customer base, and wellness brand platform will **accelerate Nextra's product launch** and consumer education efforts.



**Overall Wellbeing:** Meluka Australia's formulations are developed for easy, daily use, promoting gut health as a foundation for immune function, skin health, cognitive performance, mental wellbeing, and overall vitality.



Meluka Australia's **number 1 selling SKU** is a postbiotic drink, **P3 Gut Builder**, formulated for maximum solubility and bioavailability, to deliver rapid absorption and gut health benefits. Trusted with a high product loyalty, **8 out of 10** rated it **5 stars**<sup>1</sup>, while **9 out of 10** reported noticeable improvement **within just 1 month**<sup>2</sup>.



1/245 Churchill Ave, Subiaco WA 6008

+61 8 6465 5500

[info@evehealthgroup.com.au](mailto:info@evehealthgroup.com.au)

[WWW.EVEHEALTHGROUP.COM.AU](http://WWW.EVEHEALTHGROUP.COM.AU)

INSPIRED *by* NATURE,  
PASSION *for* WELLNESS.